The Effect of Hemodialysis vintage on pulmonary functions in patients with End Stage Renal Disease

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Hesham Atef Abouellail ◽  
Hussien Sayed Hussien ◽  
Riham Hazem Raafat ◽  
Ahmed Ibrahim El-Sayed Ibrahim
Keyword(s):  
Renal Disease ◽  
Lower Limb ◽  
End Stage Renal Disease ◽  
Chronic Hemodialysis ◽  
University Hospitals ◽  
Pulmonary Functions ◽  
Limb Edema ◽  
Stage Renal Disease ◽  
End Stage ◽  
Incident Cases

Abstract Background Chronic kidney disease (CKD) is an irreversible and progressive disorder characterized by loss of kidney function. CKD gradually progresses to end-stage renal disease (ESRD). ESRD patients eventually need renal replacement therapy via dialysis (subdivided into hemodialysis and peritoneal dialysis) or kidney transplantation in order to survive. Aim of the Work To see the effect of hemodialysis vintage on pulmonary function in patients with ESRD in Ain-Shams University Hospitals. Methods This was a prospective study at the Ain-Shams University hospitals for six month duration on patient with ESRD on regular dialysis, 100 patients were chosen for this study, divided into 2 groups each group consists of 50 patients. Incident group (on chronic hemodialysis for 1-6 months duration) and Prevalent group (on chronic hemodialysis for more than 2 years). Results this study reveals that there was statistically higher indices among incident compared to prevalent hemodialysis research groups before and after hemodialysis as regards improved Pulmonary Functions. Conclusion prevalent cases on hemodialysis sessions have been improved clinically as regards basal crepitations and lower limb edema but didn't improve significantly in comparison to incident cases as regards Pulmonary functions on the other hand incident cases have been improved as regards Pulmonary functions In a more significant manner then prevalent cases but didn't improve as regards clinical basis concerning lower limb edema and basal crepitations.

Relationship Between Volume Status and Blood Pressure in Children with End Stage Renal Disease on Chronic Hemodialysis

2007 ◽  
Vol 7 (2) ◽  
pp. 210-215
Author(s):  
Fatina I. Fadel ◽  
Samar M. Sabry ◽  
Azza M.O. Abdel Rahm ◽  
Emad Eldin E. Salama ◽  
Marwa M. El-Sonbaty
Keyword(s):  
Blood Pressure ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Chronic Hemodialysis ◽  
Volume Status ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Phase IIa Study of the Immunogenicity and Safety of the Novel Staphylococcus aureus Vaccine V710 in Adults with End-Stage Renal Disease Receiving Hemodialysis

2012 ◽  
Vol 19 (9) ◽  
pp. 1509-1516 ◽  
Author(s):  
Moustafa Moustafa ◽  
George R. Aronoff ◽  
Chandra Chandran ◽  
Jonathan S. Hartzel ◽  
Steven S. Smugar ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Geometric Mean ◽  
Surface Protein ◽  
Chronic Hemodialysis ◽  
Content Type ◽  
Primary Hypothesis ◽  
Stage Renal Disease ◽  
End Stage

ABSTRACTBacteremia is the second leading cause of death in patients with end-stage renal disease who are on hemodialysis. A vaccine eliciting long-term immune responses againstStaphylococcus aureusin patients on chronic hemodialysis may reduce the incidence of bacteremia and its complications in these patients. V710 is a vaccine containing iron surface determinant B (IsdB), a highly conservedS. aureussurface protein, which has been shown to be immunogenic in healthy subjects. In this blinded phase II immunogenicity study, 206 chronic hemodialysis patients between the ages of 18 and 80 years old were randomized to receive 60 μg V710 (with or without adjuvant), 90 μg V710 (with adjuvant), or a placebo in various combinations on days 1, 28, and 180. All 201 vaccinated patients were to be followed through day 360. The primary hypothesis was that at least 1 of the 3 groups receiving 2 V710 doses on days 1 and 28 would have a ≥2.5 geometric mean fold rise (GMFR) in anti-IsdB IgG titers over the baseline 28 days after the second vaccination (day 56). At day 56, all three groups receiving 2 doses of V710 achieved a ≥2.5 GMFR in anti-IsdB antibodies compared to the baseline (Pvalues of <0.001 for all 3 groups), satisfying the primary immunogenicity hypothesis. None of the 33 reported serious adverse experiences were considered vaccine related by the investigators. V710 induced sustained antibody responses for at least 1 year postvaccination in patients on chronic hemodialysis.

Impact of First Dialysis Modality on Outcome of Patients Contraindicated for Kidney Transplant

2006 ◽  
Vol 26 (2) ◽  
pp. 231-239 ◽  
Author(s):  
Luc Frimat ◽  
Pierre-Yves Durand ◽  
Carole Loos–Ayav ◽  
Emmanuel Villar ◽  
Victor Panescu ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Kidney Disease ◽  
Renal Disease ◽  
Kidney Transplant ◽  
End Stage Renal Disease ◽  
Role Limitation ◽  
Stage Renal Disease ◽  
End Stage ◽  
Incident Cases

Background We compared, in patients contraindicated for kidney transplant, outcomes between those patients who were only on hemodialysis (HD) and those who were given peritoneal dialysis (PD) as first renal replacement therapy (RRT). Design Prospective, population-based cohort study of incident cases of end-stage renal disease between June 1997 and June 1999. Setting A network of dialysis care: NEPHROLOR, that is, all the renal units in Lorraine, one of the 22 French administrative regions (population over 2.3 million people). Participants 387 patients were contraindicated for kidney transplant during the first 2 years of RRT: 284 were on HD, 103 on PD. Mean age was 67.6 ± 11.3 years for HD patients and 70.8 ± 11.4 years for PD patients ( p = 0.015). Main Outcome Measures Mortality until June 2003, hospitalization over the 2 first years of RRT, and Kidney Disease and Quality of Life Short Form (KDQOL-SF) 6 and 12 months after initiation of RRT. Results HD patients were more likely to die from cardiac or cerebrovascular causes, PD from cachexia or withdrawal from dialysis. Whatever mode of RRT, the unadjusted 2-year and 5-year survival rates were similar ( p = 0.98). The rate of total duration of hospital stay per month of RRT was similar in HD and PD groups: 2.7 ± 4.5 and 2.9 ± 4.2 days respectively ( p = 0.7). PD was associated with better quality of life than HD. The dimensions Role limitation due to emotional function, Burden of kidney disease, and Role limitation due to physical function ranked first, second, and third for PD. Conclusion In Lorraine, end-stage renal disease patients who were given PD as first-line RRT had no excess of death risk or hospitalizations, and better quality of life the first year of RRT.

Utilization of Peritoneal Dialysis in the Acute Setting

2007 ◽  
Vol 27 (3) ◽  
pp. 328-331 ◽  
Author(s):  
Daniela Ponce Gabriel ◽  
Juan Fernández-Cean ◽  
André Luis Balbi
Keyword(s):  
Peritoneal Dialysis ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
High Volume ◽  
Infectious Complications ◽  
Chronic Hemodialysis ◽  
Attractive Alternative ◽  
Acute Setting ◽  
Stage Renal Disease ◽  
End Stage

Peritoneal dialysis (PD), although classically described and utilized in the treatment of patients with end-stage renal disease, can also be utilized in the acute setting in different clinical situations. Recent studies showed that, in patients with acute renal failure, it is possible to obtain reasonable dialysis doses with adequate metabolic and electrolytic control and low incidence of complications by utilizing continuous PD through a cycler at high volume. In patients with congestive heart failure without end-stage renal disease, PD is capable of promoting clinical improvement with slow removal of liquids, becoming an attractive alternative for situations of rapidly or slowly worsening cardiac function. In patients submitted to chronic hemodialysis but who have vascular access difficulties, PD can also be utilized as a “bridge,” thereby avoiding the use of central venous catheters, which can be associated with infectious complications such as bacterial endocarditis. New studies must be realized showing other indications for PD.

Sign in / Sign up

Export Citation Format

Share Document